Provided by Tiger Fintech (Singapore) Pte. Ltd.

Edgewise Therapeutics, Inc.

13.03
+0.02000.15%
Post-market: 12.95-0.0800-0.61%16:10 EDT
Volume:361.18K
Turnover:4.70M
Market Cap:1.37B
PE:-8.41
High:13.22
Open:13.11
Low:12.86
Close:13.01
Loading ...

Edgewise Therapeutics Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
30 Jun

Edgewise Therapeutics initiated with a Buy at H.C. Wainwright

TIPRANKS
·
30 Jun

Edgewise Therapeutics, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating

THOMSON REUTERS
·
30 Jun

Edgewise's Sevasemten Program Poised to Succeed in Becker Muscular Dystrophy, RBC Capital Says

MT Newswires Live
·
27 Jun

Wedbush Cuts Price Target on Edgewise Therapeutics to $35 From $40, Keeps Outperform Rating

MT Newswires Live
·
27 Jun

RBC Capital Remains a Buy on Edgewise Therapeutics (EWTX)

TIPRANKS
·
27 Jun

Edgewise Therapeutics Announces Positive Sevasemten Results

TIPRANKS
·
27 Jun

BUZZ-Edgewise Therapeutics falls after mid-stage study data found insufficient for accelerated approval

Reuters
·
27 Jun

BRIEF-Edgewise Therapeutics Reports Positive Results On Sevasemten Program

Reuters
·
26 Jun

Edgewise Therapeutics Inc. Advances Sevasemten Program with Positive FDA Feedback and Clear Path for Becker Therapy Approval

Reuters
·
26 Jun

Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies

THOMSON REUTERS
·
26 Jun

Edgewise Therapeutics Inc - New Data Shows Sustained Disease Stabilization in Becker up to Three Years

THOMSON REUTERS
·
26 Jun

Edgewise Therapeutics Inc - to Meet With FDA in Q4 2025 to Discuss Phase 3 Design

THOMSON REUTERS
·
26 Jun

Edgewise Therapeutics Price Target Maintained With a $48.00/Share by RBC Capital

Dow Jones
·
05 Jun

Edgewise Therapeutics to Present at Annual Goldman Sachs Global Healthcare Conference

Reuters
·
03 Jun

Treehouse Foods, GeneDx Holdings See Activist Action -- Barrons.com

Dow Jones
·
17 May

Edgewise Therapeutics Inc. to Present at RBC Capital Markets Global Healthcare Conference

Reuters
·
14 May

Wedbush Adjusts Price Target on Edgewise Therapeutics to $40 From $43, Maintains Outperform Rating

MT Newswires Live
·
09 May

Edgewise Therapeutics' Q1 Net Loss Widens; Shares Down Over 3%

MT Newswires Live
·
08 May

Edgewise Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
08 May